SequelSEC

ROCKET PHARMACEUTICALS, INC. RCKT

Pharmaceutical Preparations · CIK 0001281895 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$231.75M
Fiscal year ended 2025-12-31
Free cash flow
-$190.45M
Fiscal year ended 2025-12-31

ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and net income of -$223.12M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ROCKET PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ROCKET PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$231.75M-$273.20M-$259.66M-$224.34M-$167.25M-$134.30M-$76.15M-$71.16M-$19.77M-$7.57M
Net income-$223.12M-$258.75M-$245.60M-$221.86M-$169.07M-$139.70M-$77.27M-$74.52M-$19.58M-$7.57M
Research & development$142.02M$171.24M$186.34M$165.57M$125.48M$105.44M$57.91M$53.27M$14.92M$5.99M
Weighted-average diluted sharesshares 111.12Mshares 94.81Mshares 84.01Mshares 68.15Mshares 63.24Mshares 55.38Mshares 49.01MUnavailableUnavailableUnavailable
Pretax income-$223.12M-$258.75MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.01$-2.73$-2.92$-3.26$-2.67$-2.52$-1.58UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$86.50M$101.96M$73.32M$58.77M$41.77M$28.86M$18.24M$17.89M$4.86M$1.58M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ROCKET PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$77.56M$163.64M$55.90M$140.52M$232.69M$297.10M$185.38M$111.36M$18.14M$29.80M
Total assets$330.45M$527.70M$566.34M$551.81M$497.02M$590.82M$372.12M$251.31M$20.15M$129.65M
Current assets$192.73M$378.18M$378.22M$364.06M$392.06M$487.34M$307.75M$209.09M$18.96M$128.35M
Total liabilities$53.23M$64.47M$73.77M$62.12M$42.30M$87.30M$64.82M$57.28M$4.63M$56.48M
Current liabilities$30.21M$40.68M$48.50M$39.17M$22.17M$32.62M$18.31M$15.37M$4.52M$7.04M
Total equity incl. NCI$277.22M$463.23M$492.57M$489.69M$454.72M$503.52M$307.30M$194.04M$15.52M$8.37M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$39.15M$39.15M$39.15M$39.20M$30.82M$30.82M$30.82M$30.82M$0Unavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$1.59M

Cash flow

ROCKET PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$190.01M-$209.72M-$194.92M-$178.14M-$121.16M-$74.64M-$64.66M-$53.79M-$15.96M-$5.50M
Capital expenditures$440.00K$5.86M$16.44M$8.36M$7.62M$20.61M$23.27M$1.45M$760.00K$335.00K
Investing cash flow$103.77M$131.71M-$98.07M-$69.33M$18.85M-$96.59M-$39.01M-$5.27M-$760.00K-$335.00K
Financing cash flow$148.00K$185.74M$208.40M$155.29M$37.68M$282.99M$177.79M$153.50M$25.41M$16.00K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$48.92M-$50.24M
Stock-based compensation$37.06M$43.92M$39.41M$31.01M$29.24M$18.57M$13.37M$13.60M$1.32M$274.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable$0$72.00K$0$0$0$0
Depreciation & amortization$8.90M$7.20M$4.90M$3.90M$3.20M$1.14M$426.00K$330.00KUnavailableUnavailable

Derived

ROCKET PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$190.45M-$215.59M-$211.35M-$186.50M-$128.78M-$95.25M-$87.93M-$55.24M-$16.72M-$5.84M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio6.38x9.30x7.80x9.29x17.69x14.94x16.81x13.60x4.19x18.23x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RCKT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2017-12-31

Operating, investing and financing flows differ from the reported change in cash by 40238000, beyond tolerance 1000000.

balance equationreview2016-12-31

Difference 64797000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

cash flow reconciliationreview2016-12-31

Operating, investing and financing flows differ from the reported change in cash by 44422000, beyond tolerance 1000000.